Beneficial effect on cardiac function by intravenous immunoglobulin treatment in patients with dilated cardiomyopathy is not due to neutralization of anti-receptor autoantibody

Tools

Item Type:	Article
Title:	Beneficial effect on cardiac function by intravenous immunoglobulin treatment in patients with dilated cardiomyopathy is not due to neutralization of anti-receptor autoantibody
Creators Name:	Larsson, L., Mobini, R., Aukrust, P., Gullestad, L., Wallukat, G., Waagstein, F. and Fu, M.
Abstract:	Anti-{beta} 1-adrenoceptor ({beta} 1AR) autoantibodies have been shown to be pathophysiologically important in idiopathic dilated cardiomyopathy (DCM). Treatment with intravenous immunoglobulin (IVIG) has shown beneficial effects in both DCM and ischemic cardiomyopathy. However, the underlying mechanism has not been clarified. In the present study, we therefore examined whether the improvement of cardiac function was due to neutralization of functional {beta} 1AR autoantibodies by anti-idiotypic antibodies. Autoantibodies against the {beta} 1AR was analysed in sera from patients with DCM (n = 16) and coronary artery disease (CAD) (n = 21) treated with IVIG or placebo before, 6 and 12 months. Six month after treatment, DCM patients showed increase in {beta} 1AR autoantibodies, mostly in IgG1 and IgG2, whereas in CAD patients mostly in IgG2. No changes in {beta} 1AR autoantibodies after 12 months were detected. In summary, our results indicate that improvement of cardiac function by IVIG is not due to neutralization of {beta} 1AR autoantibodies.
Keywords:	{Beta} 1-Adrenergic Receptor Autoantibodies, Cardiomyopathy, Intravenous Immunoglobulin, Isotype
Source:	Autoimmunity
ISSN:	0891-6934
Publisher:	Taylor & Francis
Volume:	37
Number:	6-7
Page Range:	489-493
Date:	1 January 2004
Official Publication:	https://doi.org/10.1080/08916930400011684
PubMed:	View item in PubMed

Repository Staff Only: item control page